On Quality Standards, WHO suspends TB drugs from Indian Company

  • News
  • March 31, 2016

The World health Organisation has suspended the approval of Tuberculosis drugs made by Indias Svizera Labs, a major supplier to developing countries following an investigation into standards.

The United Nation agency which acts as a drug watchdog in market said that it had suspended all its TB products made at Svizera’s Mumbai site because manufacturing standards and quality management were unreliable.

It also said that independent agencies should retest batches of medicines already on the market and it might be necessary to recall supplies, depending on the outcome of those tests.

This is a fresh blow for India’s pharmaceuticals industries cheap generic medicines to countries worldwide but has been tarnished by series of quality problem in recent times.

 

  • Related Posts

    • News
    • May 27, 2025
    • 235 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    • News
    • February 1, 2025
    • 352 views
    Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

    New Delhi: Healthcare leaders expressed overall satisfaction over Union Budget 2025 except for a letdown or two. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), though appreciated…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India

    India’s herbal and ayurvedic OTC market set to outpace global growth

    India’s herbal and ayurvedic OTC market set to outpace global growth

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug